Helica

About Helica

Built on a real genome,
by someone who wanted better answers.

Kyle Kreick — the founder — paid for a Nucleus Genomics subscription in 2025 expecting clinical-grade interpretation of his whole genome. What came back was, in his words, “thin.”

A handful of trait calls. A few risk scores. No real depth on the pharmacogenomic findings he actually cared about. A polygenic risk score for one condition that — when he checked the underlying paper — wasn’t validated in his ancestry.

He ran his own analysis pipeline against his CRAM file over the course of a few weeks: PharmCAT and Aldy for pharmacogenomics, AnnotSV for structural variants, T1K for HLA, dual-key PRS scoring for the major panels, ACMG-grade variant classification. The findings were real and several were actionable. Among them: nine pharmacogenomic findings worth flagging, including an ABCG2 poor-metabolizer call relevant to rosuvastatin, and a CYP2D6 *41/*41 intermediate-metabolizer status that affects a list of common antidepressants.

Those weren’t in the Nucleus report.

The natural question: if a curious adult with a finance background and a graphics card can find nine actionable PGx findings on his own genome, why isn’t the consumer-genomics industry shipping that depth as a product?

That’s Helica.

What we believe

A few principles, plainly stated.

01

Your genome is yours.

You should be able to take a file you already paid to generate — from 23andMe, Ancestry, Nucleus, Sequencing.com, anywhere — and get a credible interpretation of it without re-paying for sequencing or signing up for an ecosystem.

02

Findings should cite their sources.

Every clinical claim in Helica links to its underlying evidence: a CPIC guideline, a ClinVar classification, a PGS Catalog entry, a peer-reviewed paper. If we can't cite it, we don't show it.

03

The interface should be a conversation.

Most genome reports are static PDFs nobody reads twice. Genetics is interesting because it's contextual — what does this variant mean for me, given the medications I'm on? — and that conversation is what unlocks the value.

04

Reanalysis is the actual subscription value.

Genomes don't change. The science around them does, constantly. A finding from 2022 may read differently in 2026. Re-running your file every quarter against the latest evidence is the work we do for you.

05

Pharmacogenomics is the entry point.

It's the highest-action-per-finding category, the cleanest regulatory path, and the most underserved by existing consumer products. We start there because it's where a customer who has never thought about their DNA finds something that can change a real prescription decision the same week.

What we won’t do

This list matters as much as the feature list.

  • —

    No embryo screening.

    We don't interpret embryos. We don't partner with companies that do. There's no scenario where this changes.

  • —

    No longevity hand-waving.

    When we can cite a peer-reviewed validated score, we'll ship it. Until then, we leave the longevity narrative to the supplement market.

  • —

    No medical advice.

    We surface what your DNA says and we cite the source. We never recommend a drug, a dose, a treatment, or a course of action. This rule has no exceptions.

  • —

    No selling your data.

    We don't share, rent, or sell genetic data without your explicit, granular, revocable opt-in. We will not transfer customer data as part of an asset sale without 60 days' written notice and a one-click delete option.

  • —

    No fearmongering.

    Risk findings are framed as actionable information, not death sentences. A higher-than-average polygenic score is a reason to talk to a doctor, not a reason to lose sleep.

  • —

    No hype words.

    We don't "unlock your genetic potential" or help you "biohack your DNA." The data is the product. The voice is plain.

The bet

We are not trying to be the biggest consumer-genomics company.
We’re trying to be the most credible one.

The consumer-genomics market spent the last decade chasing two products: ancestry-as-entertainment and (briefly) wellness-style trait reports. The clinical depth that actually changes outcomes — pharmacogenomics, structural variants, validated polygenic risk — got pushed into expensive clinical settings most adults will never see.

23andMe filed Chapter 11 in 2025; the assets were acquired by TTAM, a nonprofit. Helix pivoted to B2B. Nucleus has been criticized for non-validated polygenic risk panels. The space cleared.

Helica is built on a single bet: that adults are willing to pay a fair monthly subscription for clinical-grade interpretation of the genome they already have, delivered in plain English, with citations they can verify, and re-run as the science evolves.

A note on the founder

Kyle Kreick is a finance and real-estate executive in Dallas — Duke alum (class of 2008, Economics, baseball scholarship), Masters in Finance from UTD, fifteen-plus years building and operating real-estate companies. Helica is the project he kept coming back to in nights and weekends after the Nucleus report. It exists because none of the obvious adults in the room were going to ship it.

The team is small and focused. We’re not raising on hype, we’re not promising to live forever, and we’re not building features we can’t credibly source.

If you’re a stranded 23andMe customer looking for somewhere reasonable to take your data, a Nucleus subscriber wanting more depth, or a curious adult who’s been on prescriptions for years and never asked the genetic question — that’s who we built this for.

See it for yourself

The report Kyle wishes he had received in 2025.

Upload the DNA file you already have. See two findings free. Decide for yourself.

Upload your DNA fileRead the methods